Intractable childhood epilepsy is a significant cause of medical morbidity and ultimately reduces quality of life. During the 1990s, there has been an unprecedented release of new antiepileptic drugs which act by novel mechanisms and have reduced adverse effects. Felbamate, gabapentin, lamotrigine, and topiramate are in current use in the United States and have been used for a wide spectrum of epileptic disorders. Aplastic anemia and hepatotoxicity now preclude felbamate except in resistant cases. Aside from the intractable partial and generalized epilepsies including the Lennox-Gastaut syndrome, the newer agents are potentially useful in the treatment of secondarily generalized seizures, juvenile myoclonic epilepsy, benign partial epilepsy with centro-temporal spikes, and children with systemic illness taking multiple medications. How these agents will ultimately fit into the overall scheme of treatment of childhood epilepsy and their role as first-line therapy are largely unexplored.
|Original language||English (US)|
|Number of pages||4|
|State||Published - Dec 1 1997|
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health